Oral contraceptives: an epidemiological perspective

Area of Science:

• Reproductive endocrinology and pharmacology
• Cardiovascular risk assessment in women's health

Background:

• Oral contraceptives (OCs) were introduced in the 1960s with high estrogen doses, offering excellent efficacy but carrying significant risks.
• Early OCs were linked to thromboembolism and cardiovascular events like myocardial infarction, prompting research into dose reduction and formulation changes.

Observation:

• Initial OC development focused on estrogen content, overlooking progestogen interactions and metabolic effects.
• Estrogen's association with thromboembolism led to the development of lower-dose formulations and different pill types (sequential, minipill).
• Sex steroids in OCs were found to alter lipoprotein and carbohydrate metabolism, contributing to cardiovascular risks.

Findings:

• Third-generation gonane progestogens demonstrate minimal impact on lipid and carbohydrate metabolism.
• Newer progestational agents maintain high efficacy and cycle control while potentially reducing serious side effects.
• Understanding OC historical development is crucial for identifying optimal estrogen-progestogen balances to maximize benefits and minimize risks.

Implications:

• Future research should focus on developing safer progestogens to further mitigate cardiovascular risks associated with oral contraception.
• The evolution of OCs highlights the importance of considering drug interactions and metabolic effects in long-term medication use.
• Continued investigation into the baseline effective and safe dosage of OCs is essential for women's reproductive health.